Uso oral do óleo de linhaça (Linum usitatissimum) no tratamento do olhoseco de pacientesportadores da síndrome de Sjögren

• Autor(a) principal: Pinheiro Jr., Manuel Neuzimar
• Data de Publicação: 2007
• Outros Autores: Santos, Procópio Miguel dos [UNIFESP], Santos, Regina Cândido Ribeiro dos [UNIFESP], Barros, Jeison de Nadai [UNIFESP], Passos, Luiz Fernando, Cardoso Neto, José
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1590/S0004-27492007000400016; http://repositorio.unifesp.br/handle/11600/3853
• topic: Dry eye syndromes; Keratoconjunctivitis sicca; Flaxseed oil; Keratitis; Sjögren's syndrome; Tears; Síndromes do olho seco; Ceratoconjuntivte seca; Óleo de semente do linho; Ceratite; Síndrome de Sjögren; Lágrimas

PURPOSE: To evaluate if oral flaxseed oil (Linum usitatissimum), which reduces the inflammation in rheumatoid arthritis, may help keratoconjunctivitis sicca's treatment in Sjögren's syndrome patients. METHODS: In a randomized clinical trial, 38 female patients with rheumatoid arthritis or systemic lupus erithematosus associated with keratoconjunctivitis sicca and Sjögren's syndrome were consecutively selected from patients of the Departament of Reumatology of the Amazonas University Hospital. Keratoconjunctivitis sicca diagnosis was based on a dry-eye symptom survey score (Ocular Surface Disease Index - OSDI®), Schirmer-I test, fluorescein break-up time, 1% Rose Bengal staining of ocular surface measured by the van Bijsterveld scale. All patients had ocular surface inflammation evaluated and quantified by conjunctival impression cytology, before and after the study. The subjects were divided into three groups with 13 (Group I), 12 (Group II) and 13 (Group III) patients. Group I received flaxseed oil capsules with a final 1 g/day dosis, Group II flaxseed oil capsules with a final 2 g/day dosis and Group III - controls - placebo, for 180 days. RESULTS: Comparing the results at the beginning and at the end of the treatment, statistically significant changes (p<0.05) in symptoms (OSDI®), ocular surface inflammation quantified by conjunctival impression cytology, Schirmer-I test and fluorescein break-up time occurred in Groups I e II when compared to controls. CONCLUSIONS: Therapy with oral flaxseed oil capsules 1 or 2 g/day reduces ocular surface inflammation and ameliorates the symptoms of keratoconjunctivitis sicca in Sjögren's syndrome patients. Long-term studies are needed to confirm the role of this therapy for keratoconjunctivitis sicca in Sjögren's syndrome.